Black Diamond Therapeutics, Inc. (BDTX) vs Milestone Pharmaceuticals Inc. (MIST)

A side-by-side comparison of Black Diamond Therapeutics, Inc. and Milestone Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — BDTX vs MIST

growth of $100 · dividends reinvested · last 7y
BDTX -95.1% (-35.0%/yr)MIST -96.4% (-37.9%/yr)BDTX compounded faster over this window
050100Start $100202120222023202420252026$5$4
BDTX MIST

BDTX vs MIST: by the numbers

  • •BDTX is the larger company ($103M vs $95M market cap).
  • •BDTX is profitable (31.95% net margin) while MIST runs a net loss (-3585.62%).

Metrics side by side

Valuation

MetricBDTXMIST
P/S ratioN/A40.61
P/B ratio1.075.22

Profitability

MetricBDTXMIST
Gross margin99.54%94.58%
Operating margin28.39%-4041.72%
Net margin31.95%-3585.62%
ROE-44.29%-461.14%
ROIC-47.54%-49.27%

Growth (annualized)

MetricBDTXMIST
Revenue CAGR (5Y)N/A-31.02%
Total return CAGR (5Y)-24.47%-33.18%

Frequently asked

Is BDTX or MIST more profitable?
BDTX runs the higher net margin — BDTX at 31.95% versus MIST at -3585.62%.
How have BDTX and MIST total returns compared?
Over the past 5 years, BDTX delivered -24.47% and MIST delivered -33.18% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.